Empire Genomics announces Japanese product distibutor
Empire Genomics (Buffalo, New York, USA) has announced that it has chosen Funakoshi as a distributor of its product portfolio for the Japanese market.
Empire Genomics (Buffalo, New York, USA) has announced that it has chosen Funakoshi as a distributor of its product portfolio for the Japanese market. The deal highlights Empire's international expansion and growth in the region.
Anthony Johnson, President and CEO of Empire Genomics, commented, “We are excited to have such a proven and expert partner in Funakoshi to service our Japanese customers and offer access to our broad genomic product and service portfolio. I am confident this relationship will provide customers with the excellent support and high quality service our customers have come to expect.”
Dr Ryoya Funakoshi, President and CEO of Funakoshi Company, Ltd., said, “We are delighted with Empire Genomics’ agreement. Empire Genomics perfectly complements our portfolio range of high-quality products and services. The Empire Genomics portfolio provides Funakoshi Company the opportunity to meet high demands for basic bioscience research and also for the pharmaceutical research in Japan.”
For more information please visit ref="http://www.empiregenomics.com">www.empiregenomics.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
